$MESO (L)
Posted my Q2 call notes in Chat- another setup I see relatively little on elsewhere
1,100 patents/pending, IP to 2044 (long runway= high strategic value to acquirer)
First-mover advantage (first and only mesenchymal stromal cell product approved by the FDA), complex
